Non-invasive Brain Tumor Molecular Diagnostics and Monitoring

The Institute of Molecular and Translational Medicine, Czech Republic

Status: Enrolling

Conditions: Brain Tumor

Treatments: Diagnostic Test: Diagnostic test

Study type: Observational

Funder types: Other

Identifiers

NCT06501521

NW25-03-00198

Details and patient eligibility

About

This prospective multicenter study aims to enroll GBM patients who will undergo repeated assessments (preoperatively and 3 months post-surgery) to detect circulating tumor cells and analyze the transcriptomic profiles of EVs in their blood. The prognostic and monitoring significance of these biomarkers to disease course (assessing treatment efficacy, resistance incidence, tumor progression) will be evaluated.

Concurrently, proteomic profiles typical of GBM will be analyzed in blood and ocular secretion samples from GBM patients, patients with low-grade gliomas, and patients without brain tumors to identify and validate novel protein biomarkers suitable for disease monitoring. Additionally, this study proposes an innovative approach to monitor GBM patients by investigating the presence of GBM-specific nucleic acid fragments in urine.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 99 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Adult patients with brain tumors -

Exclusion Criteria: No other cancer; no inflammatory disease

Trial design

200 participants in 3 patient groups

Glioblastoma multiforme

Description:

Patients with GBM

Treatment:

Diagnostic Test: Diagnostic test

Low-grade glioma

Description:

Patients with low-grade gliomas.

Treatment:

Diagnostic Test: Diagnostic test

Control group

Description:

Patients without cancer or systemic inflammation

Treatment:

Diagnostic Test: Diagnostic test